Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. InvaGen Pharmaceuticals, Inc.
EIR
•InvaGen Pharmaceuticals, Inc.•December 19, 2018

InvaGen Pharmaceuticals, Inc. – FDA EIR, Dec 19, 2018

Record Details

An FDA Pre-Approval Inspection of InvaGen Pharmaceuticals, Inc., located in Central Islip, NY, was conducted from December 10-19, 2018. The inspection, focusing on cGMP compliance for drug manufacturing and pre-approval for products like Vigabatrin for Oral Solution, revealed three significant observations documented on an FDA Form 483. Key issues included a failure to maintain active pharmaceutical ingredients under quarantine until release, with one instance where material was used in manufacturing before laboratory clearance. Secondly, the company lacked a scientifically rational or statistically sound sampling plan for in-process and finished product testing, specifically for Vigabatrin sachets. Lastly, automatic and mechanical equipment calibration was deficient, as data loggers for a stability chamber were not placed in critically identified temperature/humidity spots according to qualification reports. Verbal observations also highlighted constant issues with capsule check weighing rejections, the absence of secondary leak testing for sealed sachets (only visual inspection), and improper storage of reserve samples (open boxes, incorrect orientation). Operating under FDA's Good Manufacturing Practice regulations (21 CFR Part 211), InvaGen Pharmaceuticals' management acknowledged all observations and committed to implementing corrective actions, including developing a statistical sampling program and addressing equipment calibration and storage deficiencies. The effectiveness of these promised corrections will require further verification.

Company
InvaGen Pharmaceuticals, Inc.
Inspection date
December 19, 2018
Product type
Drugs
Office
New York District Office
People
  • Vijay Divecha (company_representative)
  • Ganeswara Reddy Pennabadi (company_representative)
  • Jose Hernandez-Guzman
  • Yogesh Gumaste (company_representative)
  • Tapas Datta (company_representative)
View Company Profile

ID · 4599863e-7506-4671-bafa-fe91fe8b268c

Violation Codes3
21 CFR 211.68(a)21 CFR 211.82(b)21 CFR 211.110(b)

Full citation text and observation details available on the Dashboard.

Other documents for InvaGen Pharmaceuticals, Inc.
  • 483 - 2026-07-17July 17, 2026
  • 483 - 2023-09-19September 19, 2023
  • 483 - 2018-12-19December 19, 2018
  • EIR - 2017-05-26May 26, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore InvaGen Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.